Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery

doi:10.1016/j.apsb.2018.07.012

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery
	Liu, Ergang 2,3,4; Zhang, Meng 2; Cui, Hui 3; Gong, Junbo 4; Huang, Yongzhuo2 ; Wang, Jianxin 1,5; Cui, Yanna 2; Dong, Weibing 4; Sun, Lu 3; He, Huining 3
刊名	ACTA PHARMACEUTICA SINICA B
	2018-10
卷号	8 期号:6 页码:956-968
关键词	Cell penetrating peptide Tat Silver nanoparticles Magnetic targeting Fe3O4 Hydraume bond
ISSN号	2211-3835
DOI	10.1016/j.apsb.2018.07.012
文献子类	Article
英文摘要	In this paper, we prepared a dual functional system based on dextrin-coated silver nanoparticles which were further attached with iron oxide nanoparticles and cell penetrating peptide (Tat), producing Tat-modified Ag-Fe3O4 nanocomposites (Tat-FeAgNPs). To load drugs, an -SH containing linker, 3-mercaptopropanohydrazide, was designed and synthesized. It enabled the silver carriers to load and release doxorubicin (Dox) in a pH-sensitive pattern. The delivery efficiency of this system was assessed in vitro using MCF-7 cells, and in vivo using null BalB/c mice bearing MCF-7 xenograft tumors. Our results demonstrated that both Tat and externally applied magnetic field could promote cellular uptake and consequently the cytotoxicity of doxorubicin-loaded nanoparticles, with the IC50 of Tat-FeAgNP-Dox to be 0.63 mu mol/L. The in vivo delivery efficiency of Tat-FeAgNP carrying Cy5 to the mouse tumor was analyzed using the in vivo optical imaging tests, in which Tat-FeAgNP-Cy5 yielded the most efficient accumulation in the tumor (6.7 +/- 2.4% ID of Tat-FeAgNPs). Anti-tumor assessment also demonstrated that Tat-FeAgNP-Dox displayed the most significant tumor-inhibiting effects and reduced the specific growth rate of tumor by 29.6% (P = 0.009), which could be attributed to its superior performance in tumor drug delivery in comparison with the control nanovehicles. (C) 2018 Chinese Pharmaceutical Association and Institute of Materia Medial Chinese Academy of Medical Sciences.
资助项目	National Key Research and Development Plan of China[2016YFE0119200] ; Young Elite Scientists Sponsorship Program by Tianjin[TJSQNTJ-2017-14] ; National Natural Science Foundation of China[NSFC 81361140344] ; National Natural Science Foundation of China[21376164] ; National Natural Science Foundation of China[81402885] ; National Natural Science Foundation of China[81373357]
WOS关键词	RESONANCE ENERGY-TRANSFER ; IRON-OXIDE ; PROTEIN TRANSDUCTION ; GREEN SYNTHESIS ; NANOPARTICLES ; SILVER ; ADRIAMYCIN ; GROWTH ; THERAPEUTICS ; MECHANISMS
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
WOS记录号	WOS:000451117700011
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279547]
专题	药物制剂研究中心
通讯作者	He, Huining; Yang, Victor C.
作者单位	1.Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 3.Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China; 4.Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China; 5.Minist Educ, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China; 6.Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
推荐引用方式 GB/T 7714	Liu, Ergang,Zhang, Meng,Cui, Hui,et al. Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery[J]. ACTA PHARMACEUTICA SINICA B,2018,8(6):956-968.
APA	Liu, Ergang.,Zhang, Meng.,Cui, Hui.,Gong, Junbo.,Huang, Yongzhuo.,...&Yang, Victor C..(2018).Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery.ACTA PHARMACEUTICA SINICA B,8(6),956-968.
MLA	Liu, Ergang,et al."Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery".ACTA PHARMACEUTICA SINICA B 8.6(2018):956-968.